Priority Lists
Protocol Posting of
Activations
Closures
Partial Closure (and NCCTG Addendum #14)
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
| Closure Date | 2002-07-18 |
Permanent Closure Effective 4/1/02.
A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
| Study Coordinator(s) | Quynh-Thu X. Le, M.D., Stephen K. Williamson, M.D., Janice Ryu, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
| Closure Date | 2002-04-01 |
Permanent Closure effective 4/1/02
Measurement of Biologic and Molecular Tumor Markers in Patients with High Grade Primary Brain Tumors Treated on SWOG-8737
| Study Coordinator(s) | Jeannette J. Townsend, M.D., Joseph A. Holden, M.D., Kurt A. Jaeckle, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
| Closure Date | 2002-04-01 |
Permanent Closure effective 3/29/02
Phase III Intergroup Randomized Comparison of Radiation Alone Vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas
| Study Coordinator(s) | Karen L. Fink, M.D.,Ph.D., Howard M. Sandler, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, Radiation Oncologists, NCORP |
| Closure Date | 2002-03-29 |
Permanent Closure effective 11/30/01
Prostate Cancer Intervention Versus Observation Trial
| Study Coordinator(s) | Daniel J. Culkin, M.D. |
| Closure Date | 2001-11-30 |
Amendments, Revisions, Memoranda
Revision #5 (NCCTG Addendum #7)
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients with Advanced Colorectal Carcinoma Previously Treated with 5-FU
| Study Coordinator(s) | Philip A. Philip, M.D.,Ph.D. |
| Participants | Members, Surgeons, NCORP |
Revision #1
Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate
| Study Coordinator(s) | David C. Smith, M.D., Maha H.A. Hussain, M.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons |
Revision #5
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer
| Study Coordinator(s) | Maha H.A. Hussain, M.D., Primo N. Lara, Jr., M.D., Wael A. Sakr, M.D., Michael A. Tainsky, Ph.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Pathologists |
Memorandum
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes, Phase III
| Study Coordinator(s) | Lori J. Pierce, M.D. |
| Participants | Medical Oncologists, Radiation Oncologists, Surgeons, NCCTG, RTOG, ACOSOG, ECOG, CALGB, NCORP, Members, NCIC-CTG, NSABP |
Revision #11
Randomized Multi-Institutional Phase III Trial of BEP and High Dose Chemotherapy Versus BEP Alone in Previously Untreated Patients With Poor and Intermediate Risk Germ Cell Tumors
| Study Coordinator(s) | Kim A. Margolin, M.D., Patrick J. Stiff, M.D., Michael F. Sarosdy, M.D. |
| Participants | Limited Institutions: SWOG Approved Autologous BMT Facilities |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required